ЛИТЕРАТУРА
1. Baustista l.E. High Blood Pressure In: Remington Pl, Brownson RC, Wegner MV, editors. Chronic disease epidemiology and control. Washington, DC: American Public Health Association, 2010.
2. lim S.S., Vos T., Flaxman A.D. et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 // lancet. 2012. Vol. 380 (9859). P. 2224-60.
3. Projections of mortality and causes of death, 2015 and 2030. http://www.who.int/healthinfo/global_burden_disease/en/.
4. World Health Organization. A global brief on hypertension: silent killer, global public health crisis. World Health Day 2013. Geneva, Switzerland: World Health Organization. 2013. P. 1e39.
5. Alcocer l., Cueto l. Hypertension, a health economics perspective // Ther Adv Cardiovasc Dis. 2008. Vol. 2. P. 147-155.
6. Chow C.K., Teo K.K., Rangarajan S. et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries // JAMA. 2013. Vol. 310. P. 959-968.
7. Touze E., Coste J., Voicu M. et al. Importance of inhospital initiation of therapies and therapeutic inertia in secondary stroke prevention: IMplementation of Prevention After a Cerebrovascular evenT (IMPACT) Study Stroke. 2008. Vol. 39. P. 1834-1843.
8. James P.A., Oparil S., Carter B.l. et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8) // J Am Med Assoc. 2014. Vol. 311. P. 507-520.
9. Lawes C.M., Vander Hoorn S., Rodgers A. Global burden of blood-pressure-related disease, 2001 // lancet. 2008. Vol. 371. P. 1513-1518.
10. Egan B.M., Zhao Y., Axon R.N. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008 // JAMA. 2010. Vol. 303. P. 2043-2050.
11. Borzecki A.M., Oliveria S.A., Berlowitz D.R. Barriers to hypertension control // Am Heart J. 2005. Vol. 149. P. 785-794.
12. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy // American Journal of Hypertension. 2006. Vol. 19 (11). P. 1190-1196.
13. World Health Organization. Adherence to long-term therapies: evidence for action. Noncommunicable Diseases and Mental Health Adherence to long-term therapies project. 2003. http://www.who.int/chp/knowledge/publications/adherence_introduction.pdf.
14. Peterson A.M., Takiya l., Finley R. Meta-analysis of trials of interventions to improve medication adherence // Am J Health Syst Pharm. 2003. Vol. 60. P. 657-665.
15. Ho P.M., Magid D.J., Shetterly S.M. et al. Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease // Arch Intern Med. 2008. Vol. 168 (3). P. 271-276.
16. Janus E.D., Bunker S.J., Kilkkinen A. et al. Prevalence, detection and drug treatment of hypertension in a rural Australian population: the Greater Green Triangle risk factor study 2004-2006 // Intern Med J. 2008. Vol. 38 (12). P. 879-886.
17. lebeau J.P., Cadwallader J.S., Aubin-Auger I. et al. The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review // BMC Fam Pract. 2014. Vol. 15. P. 723.
18. Castelino R.l., Bajorek B.V., Chen T.F. Targeting sub-optimal prescribing in the elderly: a review of the impact of pharmacy services // Ann Pharmacother. 2009. Vol. 43 (6). P. 1096-1106.
19. Castelino R.l., Bajorek B.V., Chen T.F. Retrospective evaluation of home medicines review by pharmacists in older australian patients using the medication appropriateness index // Ann Pharmacother.2010. Vol. 44 (12). P. 1922-1929.
20. Glynn l.G., Murphy A.W., Smith S.M. et al. Interventions used to improve control of blood pressure in patients with hypertension // Cochrane Database Syst Rev. 2010. Vol. (3). P. 723.
21. Uhlig K., Patel K., Ip S. et al. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis // Ann Intern Med. 2013. Vol. 159 (3). P. 185-194.
22. Higginson I.J., Carr A.J. Using quality of life measures in the clinical setting // BMJ. 2001. Vol. 322. P. 1297-1300 (2005).
23. Hayes D.K., Denny C.H., Keenan N.l. et al. Health-related quality of life and hypertension status, awareness, treatment, and control: National Health and Nutrition Examination Survey, 2001-2004 // J Hypertens. 2008. Vol. 26. P. 641-647.
24. Trevisol D.J., Moreira l.B., Kerkhoff A. et al. Health-related quality of life and hypertension: a systematic review and meta-analysis of observational studies // J Hypertens. 2011. Vol. 29. P. 179-188.
25. Ma W.J., Tang J.l., Zhang Y.H. et al. Hypertension prevalence, awareness, treatment, control, and associated factors in adults in southern China // Am J Hypertens. 2012. Vol. 25. P. 590-596.
26. National health survey. Ministry of health. Singapore. 2010.https://www.moh.gov.sg/content/moh_web/ home/Publications/Reports/2011/national_health_survey2010.html.
27. Viana l.V., leitao C.B., Grillo M.F. et al. Hypertension management algorithm for type 2 diabetic patients applied in primary care // Diabetol Metab Syndr. 2013. Vol. 5. P. 52.
28. Wu H-Y., Huang J-W., lin H-J. et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis // BMJ. 2013. Vol. 347. P. f6008.
29. Chobanian A.V., Bakris G.l., Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report // JAMA. 2003. Vol. 289 (19). P. 2560-2572.
30. Elmer P.J., Grimm R. Jr, laing B. et al. lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS) // Preventive Medicine. 1995. Vol. 24 (4). P. 378-388.
31. lichtenstein A.H., Appel l.J., Brands M. et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee // Circulation. 2006. Vol. 114(1). P. 82-96.
32. Miller E.R. 3rd, Erlinger T.P., Young D.R. et al // Results of the Diet, Exercise, and Weight loss Intervention Trial (DEW-IT) Hypertension. 2002. Vol. 40 (5). P. 612-618.
33. Chockalingam A., Campbell N., Ruddy T. et al. Canadian national high blood pressure prevention and control strategy // Can J Cardiol. 2000. Vol. 16. P. 1087e93.
34. Committee on Public Health Priorities to Reduce and Control Hypertension in the U.S. Population, Institute of Medicine of the National Academies // A Population-Based Policy and Systems Change Approach to Prevent and Control Hypertension. Washington, DC: National Academies Press. 2010. 173 p.
35. World Health Organization. WHO Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020. Geneva, Switzerland: WHO Press, World Health Organization.2013III-103.
36. World Health Organization. 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Non-communicable Diseases. Geneva, Switzerland: WHO Press, World Health Organization. 2008. 1e42 p.
37. World Health Organisation. Adherence to long-term therapies, evidence for action. Geneva 2003, http://www.who.int2.
38. Simpson S.H., Eurich D.T., Majumdar S.R. et al. A meta-analysis of the association between adherence to drug therapy and mortality // BMJ. 2006. Vol. 333. P. 15-20.
39. Robards J., Evandrou M., Falkingham J., Vlachantoni A. Marital status, health and mortality // Maturitas. 2012. Vol. 73. P. 295-299.
40. Gu D., Kelly T.N., Wu X. et al. Blood pressure and risk of cardiovascular disease in chinese men and women // Am J Hypertens. 2008. Vol. 21. P. 265-272. doi: 10.1038/ajh.2007.59.
41. Кобалава Ж.Д., Котовская Ю.В., Старостина Е.Г. и др. Проблема взаимодействия врача и пациента и контроль артериальной гипертонии в России. Основные результаты научно-практической программы АРГУС-2 // Кардиология. 2007. Т. 47, № 3. С. 38-47.
42. Конради, А. О. Недостаточная приверженность к лечению артериальной гипертензии: причины и пути коррекции / А. О. Конради, Е. В. Полуничева // Артериальная гипертензия. 2004. Т. 10: 137-143.
43. Nabi H., Vahtera J., Singh-Manoux A. et al. Do psychological attributes matter for adherence to antihypertensive medication? The Finnish Public Sector Cohort Study // J Hypertens. 2008. Vol. 26. P. 2236-2243.
44. Hassan N.B., Hasanah C.I., Foong K. et al. Identification of psychosocial factors of noncompliance in hypertensive patients // J Hum Hypertens. 2006. Vol. 20. P. 23-29.
45. Gerber B.S., Cho Y.I., Arozullah A.M., lee S.Y. Racial differences in medication adherence: A cross-sectional study of Medicare enrollees // Am J Geriatr Pharmacother. 2010. Vol.8. P. 136-145.
46. Morris A.B., li J., Krousel-Wood M. et al. Association of depression with antihypertensive medication adherence in older adults: cross-sectional and longitudinal findings from CoSMO //Ann Behav Med. 2010. Vol. 40. P. 248-257.
47. Aggarwal B., Mosca l. lifestyle and psychosocial risk factors predict non-adherence to medication // Ann Behav Med. 2010. Vol. 40. P. 228-233.
48. Krousel-Wood M.A., Frohlich E.D. Hypertension and depression: coexisting barriers to medication adherence // J Clin Hypertens (Greenwich). 2010. Vol. 12. P. 481-486.
49. Eze-Nliam C.M., Thombs B.D., lima B.B. et al. The association of depression with adherence to antihypertensive medications: a systematic review // J Hypertens. 2010. Vol. 28. P. 1785-1795.
50. Bosworth H.B., Oddone E.Z, Weinberger M. Patient treatment adherence: concepts, interventions, and measurement. Mahwah, NJ: lawrence Erlbaum Associates Publishers. 2006.
51. Osterberg l., Blaschke T. Adherence to medication // N Engl J Med. 2005. Vol. 353. P. 487-497.
52. Hanlon J.T., lindblad C.I., Hajjar E.R., McCarthy T.C. Update on drug-related problems in the elderly // Am J Geriatr Pharmacother. 2003. Vol. 1. P. 38-43.
53. Murray M.D., Callahan C.M. Improving medication use for older adults: An integrated research agenda // Ann Intern Med. 2003. Vol. 139. P. 425-429.
54. Esposito R., Izzo R., Galderisi M. et al. Identification of phenotypes at risk of transition from diastolic hypertension to isolated systolic hypertension // J Hum Hypertens. 2015.
55. Chow C.K., Teo K.K., Rangarajan S. et al. Prevalence, awareness, treatment and control of hypertension in 628 rural and urban communities from 17 high, middle and low income countries: results from the PURE (Prospective Urban Rural Epidemiology) study // JAMA. 2013. Vol. 310. P. 959-968.
56. Gee M.E., Janssen I., Pickett W. et al. Prevalence, awareness, treatment, and control of hypertension among Canadian adults with diabetes, 2007 to 2009 // Can J Cardiol. 2012. Vol. 28 (3). P. 367-374.
57. Emdin C.A., Rahimi K., Neal B. et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis // JAMA. 2015. Vol. 313 (6). P. 603-615.
58. Staessen J.A., Gasowski J., Wang J.G. et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials // lancet. 2000. Vol. 355 (9207). P. 865-872.
59. Lewington S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies // lancet. 2002. Vol. 360 (9349). P. 1903-1913.
60. Moran A.E., Odden M.C., Thanataveerat A. et al. Cost-effectiveness of hypertension therapy according to 2014 guidelines // N Engl J Med. 2015. Vol. 372 (5). P. 447-455.
61. Daskalopoulou S.S., Rabi D.M., Zarnke K.B. et al. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension // Can J Cardiol. 2015. Vol. 31 (5). P. 549-568.
62. Jamerson K., Weber M.A., Bakris G.l. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients // N Engl J Med. 2008. Vol. 359 (23). P. 2417-2428.
63. Majumdar S. Antihypertensive treatments for adults with type 2 diabetes // BMJ. 2016 Vol. 352. P. i560.
64. WHO. A Global Brief on Hypertension. Silent Killer, Global Public Health Crisis. 2013; Geneva, Switzerland: WHO, http://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en
65. Ma Y.Q., Mei W.H., Yin P. et al. Prevalence of hypertension in Chinese cities: a meta-analysis of published studies // PloS One. 2013. Vol. 8. P. 58302.
66. Hertz R.P., Unger A.N., Cornell J.A. et al. Racial disparities in hypertension prevalence, awareness, and management // Arch Intern Med. 2005. Vol. 165. P. 2098-2104.
67. Colhoun H.M., Hemingway H., Poulter N.R. Socioeconomic status and blood pressure: an overview analysis // J Hum Hypertens. 1998. Vol. 12 (2). P. 91-110.
68. Rendall M.S., Weden M.M., Favreault M.M., Waldron H. The protective effect of marriage for survival: a review and update // Demography. 2011. Vol. 48. P. 481-506.
69. Umberson D., Montez J.K. Social relationships and health: a flashpoint for health policy // J Health Soc Behav. 2010. Vol. 51. P. S54-S66.
70. lewis M.A., Butterfield R.M. Social control in marital relationships: effect of one's partner on health behaviors // J Appl Soc Psychol. 2007. Vol. 37. P. 298-319.
71. Roelfs D.J., Shor E., Kalish R., Yogev T. The rising relative risk of mortality for singles: meta-analysis and metare-gression // Am J Epidemiol. 2011. Vol. 174. P. 379-389.
72. Fessler M.T. Madmen: An evolutionary perspective on anger and men's violent responses to transgression. In: Potegal M, Stemmler G, Speilberger C, editors. International Handbook of Anger: Constituent and Concomitant Biological, Psychological, and Social Processes. New York: Springer, 2010. P. 361-381.
73. love D.A. The effects of marital status and children on savings and portfolio choice // Rev Financ Stud. 2010. Vol. 23. P. 385-432.
74. Nabi H., Vahtera J., Singh-Manoux A. et al. Do psychological attributes matter for adherence to antihypertensive medication? The Finnish Public Sector Cohort Study // J Hypertens. 2008. Vol. 26. P. 2236-2243.
75. Hassan N.B., Hasanah C.I., Foong K. et al. Identification of psychosocial factors of noncompliance in hypertensive patients // J Hum Hypertens. 2006. Vol. 20. P. 23-29.
76. James P.A., Oparil S., Carter B.l. et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8) // J Am Med Assoc. 2014. Vol. 311. P. 507-520.
77. WHO. A Global Brief on Hypertension. Silent Killer, Global Public Health Crisis. 2013; Geneva, Switzerland: WHO, http://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en
78. Конради О.А. Ключевые достижения в комбинированной антигипертензивной терапии последних лет // Артериальная гипертензия. 2012. Vol. 18 (6) 79. Mancia G. New threshold and target blood pressures in the hypertension guidelines. Which implications for the hypertensive population? // J. Hypertension. 2015. Vol. 33 (4). P. 702-703.
80. Kramer J.M., Hammill B., Anstrom K.J. et al. National evaluation of adherence to beta-blocker therapy for 1-year after acute myocardial infarction in patients with commercial health insurance // Am Heart J. 2006. Vol. 152. P. 454-458.
81. Cardinal H., Monfared A.A., Dorais M., lelorier J. A comparison between persistence to therapy in AllHAT and in everyday clinical practice: a generalizability issue // Can J Cardiol. 2004. Vol. 20. P. 417-421.
82. Van Wijk B.l., Klungel O.H., Heerdink E.R., de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs // J Hypertens. 2005. Vol. 23. P. 2101-2107.
83. Perreault S., Blais l., lamarre D. et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention // Br J Clin Pharmacol. 2005. Vol. 59. P. 564-73.
84. Chapman R.H., Benner J.S., Petrilla A.A. et al. Predictors of adherence with antihypertensive and lipid-lowering therapy // Arch Intern Med. 2005. Vol. 161. P. 1147-52.
85. World Health Organization . The World Health Report 2008: primary health care - now more than ever. Geneva: World Health Organization. 2008.
86. Tangcharoensathien V, Mills A, Palu T. Accelerating health equity: the key role of universal health coverage in the Sustainable Development Goals. BMC Med. 2015.
87. Government of India. National Rural Health Mission-key achievements. http://pib.nic.in/newsite/erelease.aspx?relid=83680.
88. National Department of Health. Ideal clinic components and definition. Pretoria: Department of Health. 2014.
89. Hist rico de Cobertura da Sa de da Familia. Brasilia, Brazil: Departamento de Aten- o B sica, 2015. http://dab.saude.gov.br.
90. lewington S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies // lancet. 2002. Vol. 360. P. 1903-1913.
91. Jaffe M.G., lee G.A., Young J.D. et al. Improved blood pressure control associated with a large-scale hypertension program // JAMA. 2013. Vol. 310. P. 699-705.
92. Handler J., lackland D.T. Translation of hypertension treatment guidelines into practice: a review of implementation // J Am Soc Hypertens. 2011. Vol. 5 (4). P. 197-207.
93. Walsh J.M., Sundaram V., McDonald K. et al. Implementing effective hypertension quality improvement strategies: barriers and potential solutions // J Clin Hypertens (Greenwich). 2008. Vol. 10 (4). P. 311-316.
94. Green B.B., Cook A.J., Ralston J.D. et al. Effectiveness of home blood pressure monitoring, web communication, and pharmacist care on hypertension control: a randomized controlled trial // JAMA. 2008. Vol. 299 (24). P. 2857-2867.
95. l ders S., Schrader J., Schmieder R.E. et al. Improvement of hypertension management by structured physician education and feedback system: cluster randomized trial // Eur J Cardiovasc Prev Rehabil. 2010. Vol. 17 (3). P. 271-279.
96. Choma N.N., Huang R.l., Dittus R.S. et al. Quality improvement initiatives improve hypertension care among veterans // Circ Cardiovasc Qual Outcomes. 2009. Vol. 2 (4). P. 392-398.